Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

comes as a result of Parse Biosciences admitting that 10x Genomics’ patents related to ATAC-seq methods and compositions are valid, enforceable, and were infringed upon by their activities.

March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq ... enforceable and infringed by Parse's use of ATAC-seq methods and compositions. "This development further validates the strength of our ...

Two recent UPC decisions have provided some guidance on the admissibility and reasonableness of auxiliary requests in revocation actions. The ...

Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with ...

Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with development and future ...